These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33162175)

  • 1. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Blanc-Durand F; Genestie C; Galende EY; Gouy S; Morice P; Pautier P; Maulard A; Mesnage S; Le Formal A; Brizais C; Richardson M; Leary A
    Gynecol Oncol; 2021 Jan; 160(1):279-284. PubMed ID: 33162175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.
    Yaniz-Galende E; Zeng Q; Bejar-Grau JF; Klein C; Blanc-Durand F; Le Formal A; Pujade-Lauraine E; Chardin L; Edmond E; Marty V; Ray-Coquard I; Joly F; Ferron G; Pautier P; Berton-Rigaud D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Bello Roufai D; Gantzer J; Rouleau E; Genestie C; Leary A
    Clin Cancer Res; 2024 Jul; 30(13):2790-2800. PubMed ID: 38669064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
    Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
    Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
    Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
    Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
    Wang YQ; Zhang Y; Jiang W; Chen YP; Xu SY; Liu N; Zhao Y; Li L; Lei Y; Hong XH; Liang YL; Li JY; Zhang LL; Yun JP; Sun Y; Li YQ; Ma J
    J Immunother Cancer; 2019 Nov; 7(1):298. PubMed ID: 31722750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature.
    Spagnol G; Ghisoni E; Morotti M; De Tommasi O; Marchetti M; Bigardi S; Tuninetti V; Tasca G; Noventa M; Saccardi C; Tozzi R; Dangaj Laniti D
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
    Kim AK; Gani F; Layman AJ; Besharati S; Zhu Q; Succaria F; Engle EL; Bhaijee F; Goggins MB; Llosa NJ; Pawlik TM; Yarchoan M; Jaffee EM; Simons HC; Taube JM; Anders RA
    Cancer Immunol Res; 2019 May; 7(5):805-812. PubMed ID: 30902819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
    Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
    Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
    Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
    Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
    Hacking S; Chavarria H; Jin C; Perry A; Nasim M
    Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.